Our results showed for the first time that LOX-1 and oxLDLs, two critical factors associated with pathologies of lipid metabolism and CaP tumor progression, are also determinants in the resistance to enzalutamide in human CRPC cell lines through NF-κB or STAT3 signaling pathway and AR and AR-V7 overexpression. This evidence concerns the gene NFKB1 and neoplasm.